Digestive Health Portfolio Growth
The Digestive Health portfolio grew almost 3% organically compared to the previous year, reaffirming the company's #1 position in long-term, short-term, and NeoMed feeding. This was supported by strong demand for ENFit conversions in North America.
Positive Financial Metrics
Generated approximately $170 million in sales from continuing operations, $0.36 of adjusted diluted earnings per share, and approximately $31 million of adjusted EBITDA from continuing operations, marking an 18% adjusted EBITDA margin.
Game Ready Portfolio Performance
The Game Ready portfolio posted its third consecutive quarter of double-digit growth compared to the prior year.
SG&A Optimization and Margin Improvement
Adjusted SG&A as a percentage of revenue improved by 180 basis points compared to the third quarter of last year and 320 basis points sequentially, primarily driven by cost savings efforts.
Transformation Progress
Achieved significant milestones in transformation efforts, including divesting respiratory health business and maintaining above-market growth in the enteral feeding business.